Could a gentle brain zap restore sensation after chemotherapy?
NCT ID NCT07673614
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This trial tests whether a non-invasive brain stimulation technique called transcranial direct current stimulation (tDCS) can help cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN). CIPN causes numbness, tingling, pain, and movement problems. The study compares active tDCS to a sham (fake) procedure in 50 cancer survivors who are no longer on active treatment. Researchers measure changes in vibration and cold detection, balance, and walking ability right after stimulation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
transcranial direct current stimulation (tDCS)
What this could lead to
If effective, tDCS could offer a non-drug way to ease nerve pain and improve movement in cancer survivors with lasting chemotherapy side effects.
What could go wrong
This is a small, early-stage trial with 50 people. The effects are temporary, and it may not work for everyone or lead to a lasting treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••